Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bolt Biotherapeutics (BOLT) just unveiled an update.
Bolt Biotherapeutics, Inc. announced board changes with the resignations of James Healy and Frank D. Lee, effective September 3, 2024; both resignations are amicable without any conflicts. Filling the vacancy, Jakob Dupont, with a robust background in biopharmaceuticals and multiple drug approvals to his credit, joins the board. His term as a Class II member will conclude at the 2026 annual stockholders’ meeting, and he will receive the standard compensation for his role as a non-employee director. Dupont has no undisclosed transactions that could pose conflicts of interest.
Learn more about BOLT stock on TipRanks’ Stock Analysis page.